Ruxolitinib phosphate cream is the first and only drug approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for repigmentation in nonsegmental vitiligo [1,2] ...

A controversial new treatment for vitiligo that can restore pigment to the skin might soon be offered by the NHS if it gets approved by UK health experts. Vitiligo is a condition that causes the skin ...

It was found that adding NB-UVB light therapy to ruxolitinib (Opzelura) 1.5% cream helped many vitiligo patients who did not respond early to treatment achieve faster and more noticeable skin ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Ruxolitinib cream 1.5% was associated with a significant ...

LEATHERHEAD, England--(BUSINESS WIRE)-- Incyte Biosciences UK today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for Opzelura® ...

Data served as basis for recent FDA approval of ruxolitinib cream (Opzelura™) 1.5% for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older ...

For patients with vitiligo, ruxolitinib cream results in greater repigmentation of lesions compared with vehicle control, according to a study published online Oct. 20 in the New England Journal of ...

A pair of posters presented at the American Academy of Dermatology 2023 Annual Meeting showed the efficacy of ruxolitinib cream in improving symptoms of vitiligo on the face, both as assessed by ...

The Global Vitiligo Treatment Market is expanding due to rising prevalence and innovative JAK inhibitors improving efficacy, ...

- Treatment with ruxolitinib cream (Opzelura™) resulted in facial repigmentation at Week 24, characterized by a significant proportion of patients achieving ≥75% improvement from baseline in the ...

Please provide your email address to receive an email when new articles are posted on . Opzelura (ruxolitinib) cream 1.5% is the first FDA-approved treatment for repigmentation in patients with ...

Patients with vitiligo will now have access to the first ever at-home therapy for skin repigmentation approved by the Food and Drug Administration. Jim Lee, vice president for Incyte’s head ...